Imperial Wins International Creative Awards. Learn More

Imperial Clinical Research Services Blog
  • Services
    • Study and Site Print Materials
    • Clinical Trial Translation Management
    • Ancillary Trial Supplies and Equipment
    • Clinical Trial Patient Engagement
    • CRO-Centered Services
    • A La Carte Services
  • Resources
    • Blog
    • Ebooks
    • Case Studies
  • About
    • News
    • Corporate Responsibility
  • Contact
    • Career Opportunities
    • Contact Imperial
  • Blog
  • Marketplace
  • Services
    • Study and Site Print Materials
    • Clinical Trial Translation Management
    • Ancillary Trial Supplies and Equipment
    • Clinical Trial Patient Engagement
    • CRO-Centered Services
    • A La Carte Services
  • Resources
    • Blog
    • Ebooks
    • Case Studies
  • About
    • News
    • Corporate Responsibility
  • Contact
    • Career Opportunities
    • Contact Imperial
  • Blog
  • Marketplace
Author

Imogen Cheese

Imogen Cheese

Imogen is Imperial’s director of business development for the U.K. and Europe. She has 20 years of business management experience with a deep understanding of trial setup and recruitment in the clinical sector. She is founder and director of Melanoma Patient Conference CIC, a non-profit education and support group that holds an annual conference for 300 melanoma patients. Imogen is an energetic advocate for the patient community, and speaks frequently at events internationally, providing guidance for ongoing initiatives that impact patients. She believes that an informed patient is the best partner for long term success in clinical trials.

    Imogen speaking at the Clinical Monitoring & Patient Recruitment Retention Summit
    Business InsightsLife-Science EventsPatient EngagementPatient Recruitment and Retention

    Summit Reveals Clinical Trial Challenges and Solutions

    by Imogen Cheese December 1, 2022
    written by Imogen Cheese

    My colleague Frances Bentley and I had the privilege of attending the 8th Annual Clinical Monitoring and Patient Recruitment Retention (CMPRR) Summit in Barcelona. Several clinical trial challenges and solutions were discussed.

    I was there to present a talk titled “Exploring the Hidden Challenges to On-Time Study Startup.” I also had the honor of serving as chairperson of the entire event at the request of organizer Sachin Sharma.

    A well-designed conference has or should have, topics of direct interest to all who attend. Considering the diverse backgrounds of delegates, this represented a challenge. In-person attendees were from various CROs and sponsors, plus vendors from a variety of areas, including decentralized trials, risk monitoring, and startups. All offered innovative ways to capture or manage data, site teams, physicians, and even patients. So, there were plenty of topics surrounding clinical trial issues.

    A prominent theme, as expected, covered the patient and site burden and different ways these burdens could be minimized whilst not greatly affecting risk or data. From my perspective as chair, it was interesting to see how presentations aligned on this subject, which fostered fantastic discussions during networking breaks.

    Clinical Monitoring & Patient Recruitment Retention Summit

    The topic of training came up frequently in presentations. Many sites face pressures due to too little training, rushed training, and little support, especially for complicated studies. Another critical focus of many talks (including my own) was patient training, education, and improved understanding of the different steps involved in the study.

    Site Clinical Trial Challenges

    Michaela Vancova, managing director of Clinical Research Center, led a panel discussion looking at the challenges from the site perspective. Studies are more complicated than ever before. Whilst there are great benefits to patients in the long term from trials that are more flexible, the strain on sites, which are often already overburdened, is immense.

    One of her panelists, Eva Turpel Kantor of Octapharma, said her wish for CROs would be to think back 15 years to when trials were less complicated. Almost all trials had similar designs. Clinical research associates and site teams had more training and support for studies, and the studies were all more inherently similar than today. Today’s studies require far more tasks and steps that impact site teams.

    Site personnel take on many more tasks: more reporting, more monitoring, and an ever-increasing number of systems and procedures to learn and understand. In order to keep costs down and accelerate startup, training needs to be improved. All parties need to get better at setting expectations and understanding what the study aims to achieve. And an understanding of the elements needed to ensure study success.

    There were interesting and surprising challenges seen at the site level, challenges that are known but frequently not discussed or addressed. In many countries, especially in Eastern Europe, not all sites have study coordinators. During site selection, the site may claim to have these positions filled. However, in reality, the role is managed by multiple people. This has a perilous knock-on effect resulting in poor data quality and overburdened teams. This then creates the common scenario of the regional clinical research associates providing the needed additional support to boost their income. This is called double dipping. It is well known, yet hard to monitor.

    Finding Participants

    Mark Bradley, founder and CEO of PeopleWith, highlighted the critical challenge surrounding electronic health data needed to undertake many trials. Of the 123 countries listed in a world health data survey, only 57 have electronic data records. As a result, we are all competing and recruiting from the same limited pool of patients. As an industry, we are missing out on billions of additional patients and trial participants who have less advanced health care and could benefit from clinical trial participation.

    This was echoed in a talk by Janusz Kabata, CEO of gp4resarch. He told us that the geographical barriers on traditional site models actually exclude more than 90 percent of patients from trial participation.

    Joseph Lovett of Medidata gave a similar perspective. He pointed out that the Covid pandemic has led to an 80 percent drop in new patients entering clinical trials and the following paints a disconcerting picture:

    1. Increasingly challenging trials and trial design
    2. Inadequate training and support for site teams
    3. Increasing costs and financial pressures
    4. Challenge to find patients in the right geographical region
    5. Patients in the right locations are apprehensive about trial participation post-Covid

    Recruiting in Developing Countries

    Thankfully, Day 2 of the conference gave hope, inspiration, and a glimmer of light at the end of the tunnel!

    Elizabeth Barabash of GaeaOÜ started the ball rolling with a fascinating presentation looking at the challenges and benefits of recruiting in developing countries.

    She said developing countries are effectively a blank canvas with the opportunity to implement best-in-class technologies. This drives significant innovation and has a hugely beneficial impact at a broader level on a country’s medical development.

    She did warn, however, that it takes time and resources to get up to speed in developing countries. This can involve high costs. Yet when time is taken at the start, with an eager patient population and high interest and commitment from site teams, studies can recruit incredibly well, even ahead of time.

    Oncology: Only a Fraction of Patients Participate

    Selin Kurnaz, cofounder and CEO of Massive Bio, talked about a market where there is a great need for clinical trials: oncology. She shared that only six percent of oncology patients globally are offered clinical trials. In 2021, 18 million people were diagnosed with cancer, and this is a market with accelerated growth. An increase in clinical trials is beneficial to the industry and has an enormous social benefit.

    She provided a statistic of great interest to me: 85 percent of cancer care in the U.S. is handled at the community level and not at the larger cancer trial specialist centers. This reveals that managing patient logistical issues, information issues, and the patient burden (especially the financial impact) is critical. This point came up several times during the summit, including in my presentation. We must, as an industry, consider and allow for the increasing patient burden when we design trials.

    Engaging all Stakeholders

    The last session I want to share with you was a fabulous panel discussion led by Estrella Garcia from Almirall. Her talk included three excellent panelists. The key message within the forum was the importance of developing solutions in collaboration with all stakeholders, with the end goal of making life easier for patients and sites.

    The approach they discussed had a higher initial cost. However, with a willing sponsor and excellent communication among the CRO, sites, and vendors, the studies had a 30 percent higher retention rate! They closed out quicker, meaning the drug was able to reach the market sooner.

    Clinical Trial Challenges are Universal and Fixable

    The talks across both days were engaging. The mix of delegates worked very well, too. It’s a conference that I highly recommend. The common themes that impact studies, from study startup and delays with enrollment and retention, are universal. But they are also fixable.

    Imogen in Barcelona after the CMPRR Summit

    Imogen visits Parc Guell in Barcelona

    Small conferences like this provide valuable opportunities for people in the industry to dig deep into an understanding of the challenges faced by other stakeholders. Shifting your angle of perception can help you see clinical trial challenges and delays from the viewpoint of others. In doing so, resolutions are more easily obtained. The networking was also just as valuable.

    After the conference finished, I took a few days of vacation. I enjoyed the wonderful sights of Barcelona with my husband whilst my U.S. colleagues enjoyed their Thanksgiving holiday. A lot to be thankful for!

    For more information on overcoming hidden delays in clinical study startup, check out this blog: https://www.imperialcrs.com/blog/2022/10/21/clinical-study-startup-and-execution-hidden-causes-behind-big-delays/ and contact us to find out how we can help.

     

    Clip of Imogen Cheese speaking at the CMPRR summit

     

    December 1, 2022 0 comment
    1 FacebookTwitterLinkedinEmail
  • Patient EngagementPatient Recruitment and Retention

    Trial Challenges: Overcoming Objections to Study Placebo Use

    by Imogen Cheese June 14, 2022
    by Imogen Cheese June 14, 2022

    I was asked to give my perspective on placebo-controlled trials. Using a study placebo presents challenges in recruitment and retention, especially because participants tend to hope that joining a study will lead to a positive treatment response. As I have mentioned in quite a few…

    0 FacebookTwitterLinkedinEmail
  • Business InsightsLife-Science Events

    Fresh Initiatives Revealed for Clinical Studies

    by Imogen Cheese May 24, 2022
    by Imogen Cheese May 24, 2022

    The Outsourcing In Clinical Trials (OCT) Europe conference held in Barcelona was fully face-to-face. No prerecorded talks! A conference hall heavy with exhibitors for clinical studies. With hundreds of delegates walking around laughing and chatting, all enjoying the return to business as usual! In-person conferences…

    2 FacebookTwitterLinkedinEmail
  • Patient EngagementPatient Recruitment and Retention

    Clinical Trial Participants Sound Off

    by Imogen Cheese April 26, 2022
    by Imogen Cheese April 26, 2022

    My colleagues and I attend several international conferences every year. We are particularly interested in discussions surrounding clinical trial participants and patient engagement, as this is an area where Imperial is involved with support for our sponsor and CRO clients. It’s reassuring to see and…

    3 FacebookTwitterLinkedinEmail
  • Life-Science EventsPatient EngagementPatient Recruitment and Retention

    Patient Engagement in the Evolving World of Clinical Trials

    by Imogen Cheese March 23, 2022
    by Imogen Cheese March 23, 2022

    I was delighted to speak at the 2022 KPM Morgan Operational Excellence in Clinical Trials (OECT) Summit in Berlin. My topic was one I am passionate about – patient engagement. I was happy to see others speak about this important subject, too. Industry Voices on…

    0 FacebookTwitterLinkedinEmail
  • Life-Science Events

    Getting Back Out There: SCOPE 22 Summit Unites Colleagues

    by Imogen Cheese February 24, 2022
    by Imogen Cheese February 24, 2022

    Shhh! Don’t tell anyone, but work conferences are about more than clients! After spending most of 2021 desperately waiting for conferences to start up again and work travel to return, the SCOPE 22 Summit appeared with a whirl of activity. It came as a shock…

    0 FacebookTwitterLinkedinEmail
  • Life-Science Events

    Patient Recruitment Changes Revealed as Trials Industry Reunites

    by Imogen Cheese December 16, 2021
    by Imogen Cheese December 16, 2021

    When you’ve had to wait 20 months to travel for work, you hold that first re-emergence into pre-pandemic day-to-day business activity on a high pedestal. Expectations are HIGH, and a quest for perfection sways with the giddy anticipation that once again you are actually getting…

    0 FacebookTwitterLinkedinEmail
  • Life-Science Events

    Munich Clinical Trials Summit a Virtual Success! Technology Pushed to its Limits

    by Imogen Cheese September 18, 2021
    by Imogen Cheese September 18, 2021

    Right at the start of the Covid pandemic last March, my colleague Dan McDonald and I were in Germany at the Munich OECT conference. Like an awkward tingle of electricity, there was an awareness that things might be about to change. But even with sanitizers…

    0 FacebookTwitterLinkedinEmail
  • Business Insights

    Reasons for Hope in the Covid Era

    by Imogen Cheese April 7, 2021
    by Imogen Cheese April 7, 2021

    Celebrating World Health Day is a no brainer. The very notion of a pandemic like the one we are experiencing was once unfathomable. Yet over the last year, we have watched as friends and family have fallen ill or even died as a direct result…

    0 FacebookTwitterLinkedinEmail
  • Business Insights

    Clinical Trials During COVID-19 and Beyond

    by Imogen Cheese October 22, 2020
    by Imogen Cheese October 22, 2020

    The last time I stepped on a plane was back in March… that’s roughly the same time since I drove for more than an hour, had face-to-face in person contact with a client, went a day without checking my phone 10 times for new updates,…

    0 FacebookTwitterLinkedinEmail
  • 1
  • 2

Welcome

Welcome

The Imperial blog features content of interest to life-science professionals, with a special focus on clinical trials. We hope you will enjoy our experts’ perspectives, and invite you to join the conversation by leaving your comments. Please let us know of any additional topics you would like to see covered here.

Keep in touch

Twitter Linkedin Youtube Email RSS

Popular Posts

  • 1

    Google Translate: The Unwitting Confidentiality Flaw

    April 15, 2020
  • 2

    25 Reasons People Aren’t Enrolling in Your Clinical Trial

    October 29, 2015
  • 3

    See Do Get

    August 12, 2014
  • 4

    Clinical Trial Supply Chains: The Key to Avoiding Disruptions

    May 10, 2022
  • 5

    COVID-19 Brings Pressure Testing to Ancillary Supplies and Equipment

    May 4, 2021

Categories

  • Ancillary Trial Supplies and Equipment (13)
  • Business Insights (99)
  • Clinical Trial Writing and Design (19)
  • Life-Science Events (42)
  • Patient Engagement (13)
  • Patient Recruitment and Retention (73)
  • Site Materials & Logistics (28)
  • Study Site Management (17)
  • Translation of Study Materials (15)
  • Uncategorized (1)
Imperial Clinical Research Services Blog

Imperial CRS is a global leader in clinical trial solutions and support, specializing in study and site print materials, ancillary trial supplies and equipment, clinical trial translation management, and clinical trial patient engagement.

Imperial CRS Corporate Headquarters
3100 Walkent Drive NW
Grand Rapids, MI 49544

Contact

connect@imperialcrs.com

800.777.2591

020 3887 3437

Employment

Social

© Imperial CRS, Inc. | Privacy Policy